Longevity & AgingBrain-Targeted GLP-1 Drug Could Shield Aging Minds from Alzheimer's and Parkinson's
Researchers are testing whether next-generation GLP-1 drugs — the same class as Ozempic — can protect the aging brain. A new partnership between Kariya Pharmaceuticals and NeuraLight is advancing KP405, a GLP-1 therapy specifically engineered to cross the blood-brain barrier. Unlike earlier versions designed for diabetes and obesity, KP405 uses a cell-penetrating peptide to directly access brain tissue and activate pathways linked to inflammation, energy use, and neuron survival. The collaboration also introduces AI-driven digital biomarkers to detect whether the drug is working earlier than conventional methods allow. Phase I safety trials are complete, with Phase II now in preparation.
